Exclusive Session on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) by Pfizer

Speciality: Cardiology


Speaker:

Arina Mullick | Medical Lead, Infedis Health

Description:

.A warm welcome to all the medical professionals in this interesting live Session on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) by Pfizer.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a progressive and often underdiagnosed condition characterized by the deposition of abnormal transthyretin protein in the heart tissue. Pfizer, a leading pharmaceutical company, is at the forefront of research and development in the field of ATTR-CM. 

Through innovative therapies and groundbreaking clinical trials, Pfizer aims to improve the diagnosis, management, and outcomes for patients affected by this debilitating disease. With a commitment to advancing medical science and enhancing patient care, Pfizer's efforts in the field of ATTR-CM offer hope for those living with this challenging condition.

Therefore, get an overall knowledge on detecting fetal aneuploidies in maternal blood. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemo-Free Regimen for Ph+ ALL Yields High Rate of Deep MRD Negativity

2.

Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.

3.

Cancer diagnosis does not spur improvements to survivors' diets or eating habits

4.

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

5.

Microplastics can cause malignant changes in lung cells


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot